{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:01:02Z","timestamp":1791910862623,"version":"4.3.4"},"reference-count":73,"publisher":"Jaypee Brothers Medical Publishing","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.59556\/japi.72.0759","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T07:12:47Z","timestamp":1750662767000},"page":"e35-e41","source":"Crossref","is-referenced-by-count":7,"title":["SGLT2 Inhibitors and Finerenone: A friendly Duo in the Treatment of Diabetic Kidney Disease?"],"prefix":"10.59556","volume":"72","author":[{"given":"Adlyne Reena","family":"Asirvatham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Joseph","family":"Asirvatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriraam","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"key":"key20250623071243_B1","volume-title":"IDF Diabetes Atlas,","author":"International Diabetes Federation.","year":"2021.","edition":"10th edition."},{"key":"key20250623071243_B2","doi-asserted-by":"crossref","first-page":"e000154.","DOI":"10.1136\/bmjdrc-2015-000154","article-title":"Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns\u2014NHANES 2007-2012.","volume":"4:","author":"Wu","year":"2016;","journal-title":"BMJ Open Diabetes Res Care"},{"key":"key20250623071243_B3","doi-asserted-by":"crossref","first-page":"851\u2013","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.","volume":"345:","author":"Lewis","year":"2001;","journal-title":"N Engl J Med"},{"key":"key20250623071243_B4","doi-asserted-by":"crossref","first-page":"861\u2013","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.","volume":"345:","author":"Brenner","year":"2001;","journal-title":"N Engl J Med"},{"key":"key20250623071243_B5","doi-asserted-by":"crossref","first-page":"2117\u2013","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373:","author":"Zinman","year":"2015;","journal-title":"N Engl J Med"},{"key":"key20250623071243_B6","doi-asserted-by":"crossref","first-page":"644\u2013","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377:","author":"Neal","year":"2017;","journal-title":"N Engl J Med"},{"key":"key20250623071243_B7","doi-asserted-by":"crossref","first-page":"347\u2013","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380:","author":"Wiviott","year":"2019;","journal-title":"N Engl J Med"},{"issue":"(10):","key":"key20250623071243_B8","first-page":"CD007004.","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.","volume":"10","author":"Chung","year":"2020;","journal-title":"Cochrane Database Syst Rev"},{"issue":"(12):","key":"key20250623071243_B9","doi-asserted-by":"crossref","first-page":"1715\u2013","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial.","volume":"15","author":"Ito","year":"2020;","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20250623071243_B10","doi-asserted-by":"crossref","first-page":"120\u2013","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study.","volume":"25:","author":"Wada","year":"2021;","journal-title":"Clin Exp Nephrol"},{"issue":"(23):","key":"key20250623071243_B11","doi-asserted-by":"crossref","first-page":"2219\u2013","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.","volume":"383","author":"Bakris","year":"2020;","journal-title":"N Engl J Med"},{"issue":"(1):","key":"key20250623071243_B12","doi-asserted-by":"crossref","first-page":"57\u2013","DOI":"10.1038\/ki.2009.399","article-title":"In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria.","volume":"77","author":"Perkins","year":"2010;","journal-title":"Kidney Int"},{"issue":"(6):","key":"key20250623071243_B13","doi-asserted-by":"crossref","first-page":"954\u2013","DOI":"10.2337\/dc15-0184","article-title":"Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes.","volume":"38","author":"Krolewski","year":"2015;","journal-title":"Diabetes Care"},{"issue":"(3):","key":"key20250623071243_B14","first-page":"246\u2013","article-title":"Diabetic kidney disease with and without albuminuria.","volume":"20","author":"Richard","year":"2011;","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"(24):","key":"key20250623071243_B15","doi-asserted-by":"crossref","first-page":"3273\u2013","DOI":"10.1001\/jama.289.24.3273","article-title":"Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus.","volume":"289","author":"Kramer","year":"2003;","journal-title":"JAMA"},{"issue":"(5):","key":"key20250623071243_B16","doi-asserted-by":"crossref","first-page":"382\u2013","DOI":"10.1016\/S2213-8587(15)00094-7","article-title":"Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes.","volume":"3","author":"Porrini","year":"2015;","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20250623071243_B17","doi-asserted-by":"crossref","first-page":"215\u2013","DOI":"10.1159\/000506634","article-title":"Diabetic kidney disease: challenges, advances, and opportunities.","volume":"6:","author":"Chen","year":"2020;","journal-title":"Kidney Dis"},{"issue":"(14):","key":"key20250623071243_B18","first-page":"977\u2013","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.","volume":"329","author":"Nathan","year":"1993;","journal-title":"N Engl J Med"},{"key":"key20250623071243_B19","first-page":"2643\u2013","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.","volume":"53:","author":"Nathan","year":"2005;","journal-title":"N Engl J Med"},{"key":"key20250623071243_B20","doi-asserted-by":"crossref","first-page":"405\u2013","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.","volume":"321:","author":"Stratton","year":"2000;","journal-title":"BMJ"},{"issue":"(10):","key":"key20250623071243_B21","first-page":"761\u2013","article-title":"Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes.","volume":"172","author":"Coca","year":"2012;","journal-title":"Arch Intern Med"},{"key":"key20250623071243_B22","doi-asserted-by":"crossref","first-page":"S165\u2013","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 inhibitors and the diabetic kidney.","volume":"39:","author":"Fioretto","year":"2016;","journal-title":"Diabetes Care"},{"key":"key20250623071243_B23","doi-asserted-by":"crossref","first-page":"507\u2013","DOI":"10.1681\/ASN.2011060627","article-title":"Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes.","volume":"3:","author":"Niewczas","year":"2012;","journal-title":"J Am Soc Nephrol"},{"key":"key20250623071243_B24","doi-asserted-by":"crossref","first-page":"248\u2013","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease.","volume":"102:","author":"Tuttle","year":"2022;","journal-title":"Kidney Int"},{"issue":"(5):","key":"key20250623071243_B25","doi-asserted-by":"crossref","first-page":"319\u2013","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.","volume":"17","author":"DeFronzo","year":"2021;","journal-title":"Nat Rev Nephrol"},{"key":"key20250623071243_B26","doi-asserted-by":"crossref","first-page":"752\u2013","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications.","volume":"134:","author":"Heerspink","year":"2016;","journal-title":"Circulation"},{"issue":"(12):","key":"key20250623071243_B27","doi-asserted-by":"crossref","first-page":"2032\u2013","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities.","volume":"12","author":"Alicic","year":"2017;","journal-title":"Clin J Am Soc Nephrol"},{"issue":"(11):","key":"key20250623071243_B28","doi-asserted-by":"crossref","first-page":"1496\u2013","DOI":"10.1038\/nm.3363","article-title":"Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes.","volume":"19","author":"Hasegawa","year":"2013;","journal-title":"Nat Med"},{"key":"key20250623071243_B29","doi-asserted-by":"crossref","first-page":"580\u2013","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes.","volume":"358:","author":"Gaede","year":"2008;","journal-title":"N Engl J Med"},{"issue":"(1):","key":"key20250623071243_B30","doi-asserted-by":"crossref","first-page":"256\u2013","DOI":"10.1016\/j.kint.2020.08.012","article-title":"Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes.","volume":"99","author":"Ueki","year":"2021;","journal-title":"Kidney Int"},{"issue":"(4):","key":"key20250623071243_B31","doi-asserted-by":"crossref","first-page":"947.","DOI":"10.3390\/jcm9040947","article-title":"GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists.","volume":"9","author":"G\u00f3rriz","year":"2020;","journal-title":"J Clin Med"},{"key":"key20250623071243_B32","doi-asserted-by":"crossref","first-page":"605\u2013","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.","volume":"6:","author":"Tuttle","year":"2018;","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20250623071243_B33","doi-asserted-by":"crossref","first-page":"131\u2013","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.","volume":"394:","author":"Gerstein","year":"2019;","journal-title":"Lancet"},{"issue":"(1):","key":"key20250623071243_B34","doi-asserted-by":"crossref","first-page":"11\u2013","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.","volume":"13","author":"DeFronzo","year":"2017;","journal-title":"Nat Rev Nephrol"},{"key":"key20250623071243_B35","doi-asserted-by":"crossref","first-page":"1927\u2013","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin lowers plasma glucose concentration and improves beta-cell function.","volume":"100:","author":"Merovci","year":"2015;","journal-title":"J Clin Endocrinol Metab"},{"issue":"(6):","key":"key20250623071243_B36","doi-asserted-by":"crossref","first-page":"319\u2013","DOI":"10.1038\/nrneph.2010.58","article-title":"The RAAS in the pathogenesis and treatment of diabetic nephropathy.","volume":"6","author":"Ruggenenti","year":"2010;","journal-title":"Nat Rev Nephrol"},{"key":"key20250623071243_B37","doi-asserted-by":"crossref","first-page":"803\u2013","DOI":"10.1097\/00004872-199208000-00015","article-title":"Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?","volume":"10:","author":"van den Meiracker","year":"1992;","journal-title":"J Hypertens"},{"key":"key20250623071243_B38","doi-asserted-by":"crossref","first-page":"2295\u2013","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380:","author":"Perkovic","year":"2019;","journal-title":"N Engl J Med"},{"key":"key20250623071243_B39","doi-asserted-by":"crossref","first-page":"1436\u2013","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383:","author":"Heerspink","year":"2020;","journal-title":"N Engl J Med"},{"key":"key20250623071243_B40","doi-asserted-by":"crossref","first-page":"117\u2013","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease.","volume":"388:","author":"Herrington","year":"2023;","journal-title":"N Engl J Med"},{"key":"key20250623071243_B41","doi-asserted-by":"crossref","first-page":"561\u2013","DOI":"10.1194\/jlr.P040501","article-title":"Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy.","volume":"55:","author":"Herman-Edelstein","year":"2014;","journal-title":"J Lipid Res"},{"issue":"(1):","key":"key20250623071243_B42","doi-asserted-by":"crossref","first-page":"179.","DOI":"10.1186\/s12944-016-0350-0","article-title":"Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.","volume":"15","author":"Shen","year":"2016;","journal-title":"Lipids Health Dis"},{"key":"key20250623071243_B43","doi-asserted-by":"crossref","first-page":"509\u2013","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.","volume":"124:","author":"Merovci","year":"2014;","journal-title":"J Clin Invest"},{"key":"key20250623071243_B44","doi-asserted-by":"crossref","first-page":"457\u2013","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease.","volume":"44:","author":"Bonnet","year":"2018;","journal-title":"Diabetes Metab"},{"key":"key20250623071243_B45","doi-asserted-by":"crossref","first-page":"2617\u2013","DOI":"10.1111\/dom.13441","article-title":"Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.","volume":"20:","author":"Jaikumkao","year":"2018;","journal-title":"Diabetes Obes Metab"},{"key":"key20250623071243_B46","doi-asserted-by":"crossref","first-page":"e54442.","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of SGLT2 inhibition in human kidney proximal tubular cells\u2014renoprotection in diabetic nephropathy?","volume":"892:","author":"Panchapakesan","year":"2013;","journal-title":"PLoS One"},{"key":"key20250623071243_B47","doi-asserted-by":"crossref","first-page":"22\u2013","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.","volume":"9:","author":"Wheeler","year":"2021;","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"(10):","key":"key20250623071243_B48","doi-asserted-by":"crossref","first-page":"102638.","DOI":"10.1016\/j.dsx.2022.102638","article-title":"Finerenone in diabetic kidney disease: a systematic review and critical appraisal.","volume":"16","author":"Singh","year":"2022;","journal-title":"Diabetes Metab Syndr"},{"issue":"(2):","key":"key20250623071243_B49","first-page":"e21314.","article-title":"Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells.","volume":"35","author":"Le Billan","year":"2021;","journal-title":"FASEB J"},{"key":"key20250623071243_B50","doi-asserted-by":"crossref","first-page":"271\u2013","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside.","volume":"243:","author":"Kolkhof","year":"2017;","journal-title":"Handb Exp Pharmacol"},{"key":"key20250623071243_B51","doi-asserted-by":"crossref","first-page":"152\u2013","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.","volume":"42:","author":"Agarwal","year":"2021;","journal-title":"Eur Heart J"},{"key":"key20250623071243_B52","doi-asserted-by":"crossref","first-page":"794\u2013","DOI":"10.1536\/ihj.16-649","article-title":"High glucose stimulates mineralocorticoid receptor transcriptional activity through the protein kinase C signaling.","volume":"58:","author":"Hayashi","year":"2017;","journal-title":"Int Heart J"},{"issue":"(9):","key":"key20250623071243_B53","doi-asserted-by":"crossref","first-page":"486\u2013","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough.","volume":"3","author":"Bomback","year":"2007;","journal-title":"Nat Clin Pract Nephrol"},{"key":"key20250623071243_B54","doi-asserted-by":"crossref","first-page":"587\u2013","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.","volume":"129:","author":"Cherney","year":"2014;","journal-title":"Circulation"},{"issue":"(9):","key":"key20250623071243_B55","doi-asserted-by":"crossref","first-page":"884\u2013","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial.","volume":"314","author":"Bakris","year":"2015;","journal-title":"JAMA"},{"key":"key20250623071243_B56","doi-asserted-by":"crossref","first-page":"2252\u2013","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes.","volume":"385:","author":"Pitt","year":"2021;","journal-title":"N Engl J Med"},{"issue":"(31):","key":"key20250623071243_B57","doi-asserted-by":"crossref","first-page":"2453\u2013","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.","volume":"34","author":"Pitt","year":"2013;","journal-title":"Eur Heart J"},{"issue":"(4):","key":"key20250623071243_B58","doi-asserted-by":"crossref","first-page":"758\u2013","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.","volume":"31","author":"Katayama","year":"2017;","journal-title":"J Diabetes Complications"},{"issue":"(27):","key":"key20250623071243_B59","doi-asserted-by":"crossref","first-page":"2105\u2013","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease.","volume":"37","author":"Filippatos","year":"2016;","journal-title":"Eur Heart J"},{"issue":"(5):","key":"key20250623071243_B60","doi-asserted-by":"crossref","first-page":"1113\u2013","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease.","volume":"80","author":"Sato","year":"2016;","journal-title":"Circ J"},{"issue":"(6):","key":"key20250623071243_B61","doi-asserted-by":"crossref","first-page":"474\u2013","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.","volume":"43","author":"Agarwal","year":"2022;","journal-title":"Eur Heart J"},{"key":"key20250623071243_B62","author":"A study called FINE-REAL to learn more about the use of the drug finerenone in a routine medical care setting."},{"key":"key20250623071243_B63","doi-asserted-by":"crossref","first-page":"642\u2013","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage.","volume":"52:","author":"Kolkhof","year":"2021;","journal-title":"Am J Nephrol"},{"issue":"(11):","key":"key20250623071243_B64","doi-asserted-by":"crossref","first-page":"1397\u2013","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-reduced.","volume":"77","author":"Ferreira","year":"2021;","journal-title":"J Am Coll Cardiol"},{"issue":"(8):","key":"key20250623071243_B65","doi-asserted-by":"crossref","first-page":"1569\u2013","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial.","volume":"33","author":"Provenzano","year":"2022;","journal-title":"J Am Soc Nephrol"},{"issue":"(19):","key":"key20250623071243_B66","doi-asserted-by":"crossref","first-page":"1460\u2013","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials.","volume":"145","author":"Neuen","year":"2022;","journal-title":"Circulation"},{"key":"key20250623071243_B67","doi-asserted-by":"crossref","first-page":"36\u2013","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy.","volume":"7:","author":"Rossing","year":"2022;","journal-title":"Kidney Int Rep"},{"key":"key20250623071243_B68","doi-asserted-by":"crossref","first-page":"2991\u2013","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis.","volume":"45:","author":"Rossing","year":"2022;","journal-title":"Diabetes Care"},{"issue":"(7):","key":"key20250623071243_B69","doi-asserted-by":"crossref","first-page":"471\u2013","DOI":"10.4239\/wjd.v13.i7.471","article-title":"Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: a tale of the past two decades!","volume":"13","author":"Singh","year":"2022;","journal-title":"World J Diabetes"},{"key":"key20250623071243_B70","first-page":"gfac198.","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).","author":"Green","year":"2022;","journal-title":"Nephrol Dial Transplant"},{"issue":"(19):","key":"key20250623071243_B71","doi-asserted-by":"crossref","first-page":"1854\u2013","DOI":"10.1016\/j.jacc.2023.08.026","article-title":"Dapagliflozin in patients with heart failure and deterioration in renal function.","volume":"82","author":"Chatur","year":"2023;","journal-title":"J Am Coll Cardiol."},{"key":"key20250623071243_B72","unstructured":"KDIGO 2022: clinical practice guideline for diabetes management in chronic kidney disease. Available from https:\/\/kdigo.org\/wp-content\/uploads\/2022\/03\/KDIGO-2022-Diabetes-Management-GL_Public-Review-draft_1Mar2022.pdf"},{"issue":"(Suppl. 1):","key":"key20250623071243_B73","doi-asserted-by":"crossref","first-page":"S175\u2013","DOI":"10.2337\/dc22-S011","article-title":"Chronic kidney disease and risk management: standards of medical care in diabetes\u20142022.","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022;","journal-title":"Diabetes Care"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T07:12:57Z","timestamp":1750662777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.japi.org\/article\/japi-72-12-e35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":73,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.59556\/japi.72.0759"],"URL":"https:\/\/doi.org\/10.59556\/japi.72.0759","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}